Lipid-protamine-DNA-mediated antigen delivery.
The development of novel 'new generation' vaccine systems that is based on proteins, peptides or DNA is of great current interest. However, due to the lower efficiencies of these new generation vaccines, they are seldomly used alone. Rather, their formulations often contain adjuvants, either to enhance the immune responses or to reduce dosing. The present chapter will provide a brief overview of the recent advances in peptide-based cancer vaccine adjuvants, focusing mainly on Liposome-Protamine-DNA (LPD) nanoparticle-mediated antigen delivery.
Vangasseri
Dileep Padinjarae
DP
Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA.
Han
Su-Ji
SJ
Huang
Leaf
L
D000276:Adjuvants, Immunologic; D000818:Animals; D000941:Antigens / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D004247:DNA / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D016503:Drug Delivery Systems; D006801:Humans; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D011479:Protamines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000941:Antigens; D019496:Cancer Vaccines; D008055:Lipids; D011479:Protamines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D004247:DNA